Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance.

Literature DB >> 1094965

Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance.

Abstract

Two studies are reported; a double-blind cross-over trial of feprazone 600 mg daily and aspirin 3.6 g daily in the treatment of rheumatoid arthritis, and an uncontrolled open study of gastrointestinal tolerance in twenty rheumatoid arthritis patients with known intolerance to other drugs. The first study showed that feprazone was significantly superior to aspirin in all the parameters tested. In the second study all twenty patients showed an improvement of their gastrointestinal symptoms, nineteen reporting no symptoms at all when taking the new preparation.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1975 PMID： 1094965 PMCID： PMC1006371 DOI： 10.1136/ard.34.2.190

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

12 in total

1. DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.

Authors:
Journal: Ann Rheum Dis Date: 1959-03 Impact factor: 19.103

2. Long-term use of phenylbutazone in rheumatoid arthritis.

Authors: R M MASON; V L STEINBERG
Journal: Br Med J Date: 1960-09-17

3. Clinical experience with phenylbutazone in 205 patients.

Authors: C W DENKO; D RUML; D M BERGENSTAL
Journal: Am Pract Dig Treat Date: 1955-12

4. Clinical trial of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in painful osteoarticular conditions.

Authors: C Pasotti; C Barbieri; G Buniva; S Chierichetti
Journal: Arzneimittelforschung Date: 1972-01

5. Clinical study of a new anti-inflammatory drug: 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370).

Authors: F Dotti; R Ongari; R Carazzi; S Chierichetti
Journal: Arzneimittelforschung Date: 1972-01

6. Clinical and laboratory evaluation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in rheumatoid arthritis and ankylosing spondylitis.

Authors: G C Lignière; B Colombo; M Carrabba; P Ferrari; E Robotti
Journal: Arzneimittelforschung Date: 1972-01

10. On the healing properties of esters of D-panthenol with terpene acids, with particular reference to D-pantothenyl trifarnesylacetate.

Authors: S Casadio; A Mantegani; G Coppi; G Pala
Journal: Arzneimittelforschung Date: 1967-09

4 in total

4. An analysis of the gastro-intestinal side-effects of non-steroidal anti-inflammatory drugs, with particular reference to comparative studies in man and laboratory species.

Authors: K D Rainsford
Journal: Rheumatol Int Date: 1982 Impact factor: 2.631

4 in total

Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance.

1. DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.

2. Long-term use of phenylbutazone in rheumatoid arthritis.

3. Clinical experience with phenylbutazone in 205 patients.

4. Clinical trial of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in painful osteoarticular conditions.

5. Clinical study of a new anti-inflammatory drug: 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370).

6. Clinical and laboratory evaluation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in rheumatoid arthritis and ankylosing spondylitis.

7. A short-term double-blind controlled trial of prenazone (DA 2370) in rheumatoid arthritis.

8. Analgesics and non-steroid anti-inflammatory agents in rheumatic disease.

9. The status of phenylbutazone (butazolidin) in the treatment of rheumatic disorders.

10. On the healing properties of esters of D-panthenol with terpene acids, with particular reference to D-pantothenyl trifarnesylacetate.

1. Rectal administration of feprazone in healthy volunteers.

Review 2. Antirheumatic drugs: clinical pharmacology and therapeutic use.

3. An objective measurement of change in morning stiffness.

4. An analysis of the gastro-intestinal side-effects of non-steroidal anti-inflammatory drugs, with particular reference to comparative studies in man and laboratory species.